Rallybio (RLYB) Expected to Post Earnings on Thursday

Rallybio (NASDAQ:RLYB) will likely be releasing its results before the market opens on Thursday, August 6th. Analysts expect Rallybio to announce earnings of ($1.28) per share and revenue of $0.2160 million for the quarter.

Rallybio (NASDAQ:RLYB) last announced its quarterly earnings results on Wednesday, May 13th. The company reported ($1.46) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.20) by ($0.26). Rallybio had a negative return on equity of 55.79% and a negative net margin of 911.07%.The business had revenue of $0.21 million during the quarter, compared to the consensus estimate of $0.21 million.

Rallybio Price Performance

NASDAQ:RLYB opened at $15.96 on Wednesday. Rallybio has a fifty-two week low of $3.20 and a fifty-two week high of $17.57. The stock has a market capitalization of $84.59 million, a PE ratio of -3.68 and a beta of -0.90. The business’s 50-day simple moving average is $15.95 and its 200-day simple moving average is $11.21.

Insiders Place Their Bets

In other news, major shareholder Adar1 Capital Management, Llc bought 79,259 shares of the stock in a transaction on Wednesday, May 13th. The stock was purchased at an average price of $13.99 per share, for a total transaction of $1,108,833.41. Following the acquisition, the insider owned 909,843 shares in the company, valued at approximately $12,728,703.57. This trade represents a 9.54% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Over the last three months, insiders have acquired 146,568 shares of company stock valued at $2,050,669. 10.30% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of the company. XTX Topco Ltd grew its holdings in shares of Rallybio by 64.6% during the fourth quarter. XTX Topco Ltd now owns 97,313 shares of the company’s stock worth $67,000 after buying an additional 38,205 shares in the last quarter. Susquehanna International Group LLP boosted its position in Rallybio by 485.9% during the 3rd quarter. Susquehanna International Group LLP now owns 136,294 shares of the company’s stock worth $68,000 after acquiring an additional 113,031 shares during the last quarter. Geode Capital Management LLC boosted its position in Rallybio by 1.2% during the 4th quarter. Geode Capital Management LLC now owns 248,005 shares of the company’s stock worth $170,000 after acquiring an additional 2,996 shares during the last quarter. Citadel Advisors LLC grew its stake in shares of Rallybio by 576.1% during the 3rd quarter. Citadel Advisors LLC now owns 438,705 shares of the company’s stock worth $219,000 after acquiring an additional 373,821 shares in the last quarter. Finally, Renaissance Technologies LLC grew its stake in shares of Rallybio by 16.9% during the 4th quarter. Renaissance Technologies LLC now owns 835,692 shares of the company’s stock worth $573,000 after acquiring an additional 120,892 shares in the last quarter. 90.34% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Separately, Weiss Ratings restated a “sell (d-)” rating on shares of Rallybio in a report on Friday, May 8th. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the stock presently has an average rating of “Sell”.

Rallybio Company Profile

Rallybio Therapeutics, Inc (NASDAQ: RLYB) is a clinical‐stage biotechnology company focused on developing and commercializing therapies for people living with rare genetic diseases. The company’s scientific approach leverages diverse modalities—including monoclonal antibodies, small molecules and enzyme replacement—to address high‐unmet‐need conditions in areas such as immunodeficiency, metabolic disorders and dermatologic diseases. Rallybio’s pipeline is designed to advance through registrational clinical trials with the goal of delivering first‐in‐class or best‐in‐class therapies to patients who currently have limited or no approved treatment options.

Among Rallybio’s lead programs is RBX‐100, an investigational therapy for congenital athymia, a rare pediatric immunodeficiency.